@FierceBiotech: NIH backs effort to integrate clinical trials data into EHRs. Story | Follow @FierceBiotech
@JohnCFierce: ACT's trying a reverse split in the range of 1/20, 1/80 to get onto Nasdaq. Often hyped but interesting stem cell work. Release | Follow @JohnCFierce
@RyanMFierce: Worth the 5 mins to read @ldtimmerman 's interview with former Amgen R&D chief Roger Perlmutter. Interview | Follow @RyanMFierce
@FierceMedDev: Cipla introduces new pain-free screening tech for early detection of breast cancer in India. Story | Follow @FierceMedDev
@MarkHFierce: Researchers found five gene mutations connected to elevated blood platelet levels in African-Americans. Big finding. Release | Follow @MarkHFierce
> TG Therapeutics said that it has raised $25 million in financing, licensed worldwide rights to the CD20-targeting antibody drug Ublituximab from LFB Biotechnologies and GTC Biotherapeutics, and has made a deal to become a public company through a merger with Manhattan Pharmaceuticals ($TGTX). Release
> Amarin's ($AMRN) stock was down 11% late this morning after the company filed info with the SEC about its efforts to protect the intellectual property for its potential blockbuster cardiovascular disease drug AMR101. Filing
> Ex-Pfizer ($PFE) R&D chief John LaMattina counters the belief that drug discovery has become more difficult. Blog
> Argos Therapeutics has delayed its plans for an initial public offering, according to Renaissance Capital. Item
> Advanced Cell Technology ($ACTC) revealed plans for a reverse stock split that it hopes increases its share price enough to gain listing on the Nasdaq Global Market. Release
> Xconomy's Luke Timmerman profiles South San Francisco-based startup Cytomx Therapeutics, which has ambitious plans to engineer anti-cancer antibody drugs that are more potent than offerings from Eli Lilly ($LLY) and Amgen ($AMGN). Article
> Arena Pharmaceuticals ($ARNA) has filed paperwork to formally request European approval of its weight drug Lorcaserin. Release
Pharma News
@FiercePharma: China pharmaceuticals feel bite of healthcare reforms. Story via @Reuters | Follow @FiercePharma
> Chinese pharmas feel the squeeze of healthcare reform. Story
> Columbia Labs to cut 42% of workforce after FDA snub. News
> Indian regulators, alleging overpricing, demand $86M from Cipla. Article
> Sources: Nestle leads in Pfizer unit bid, but don't count out Danone-Mead. Piece
And Finally… Amid budgetary woes, NASA is regrouping to fund the U.S. space agency's mission to Mars. News